Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
Key Highlights
- ➤Allergan Aesthetics will present nine abstracts at the 2026 ASDS Annual Meeting.
- ➤Two Phase 4 studies examine aesthetic treatment for patients taking GLP-1-related weight-loss medications.
- ➤Investigational trenibotulinumtoxinE and BOTOX Cosmetic receive digital image analysis presentation.
- ➤Expert panel will address shifting consumer expectations, misconceptions and medical weight loss in aesthetics.
Expert Statements
Darin Messina, Senior vice president, head of aesthetics research and development, AbbVie
“Advancing aesthetic medicine starts with understanding patients' evolving needs and generating the scientific evidence to keep pace,”
Darin Messina, Senior vice president, head of aesthetics research and development, AbbVie
“We continue to build on our extensive body of clinical research, including studies of multimodal treatment approaches, to help providers make informed decisions about using our products to address a range of aesthetic concerns.”
Joely Kaufman-Janette, M.D., Board-certified dermatologist, Skin Research Institute, and study investigator
“Patients experiencing medical weight loss may have aesthetic concerns that extend beyond changes in facial volume or skin quality,”
Joely Kaufman-Janette, M.D., Board-certified dermatologist, Skin Research Institute, and study investigator
“By examining patient satisfaction and psychosocial well-being alongside changes in physical appearance, we can gain a more complete picture of their needs and support them with individualized treatment approaches throughout their aesthetic journeys.”
Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026 PR Newswire
– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital image analysis evaluating glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and BOTOX(®) Cosmetic (onabotulinumtoxinA) will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session – Expert panel to explore shifting consumer expectations, common misconceptions and medical weight loss in aesthetics, drawing on insights from the Allergan Aesthetics "What Consumers Really Want" report
Get started
Create a free account to read the full story.